Consensus Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Real-time Estimate Cboe BZX Other stock markets 15:58:23 20/06/2024 BST			5-day change	1st Jan Change
8.2 ^USD	+3.27%		+0.37%	+211.11%

06-18	Summit Therapeutics Inc. announced that it has received $199.999998 million in funding from Baker Bros. Advisors LP	CI
06-13	Summit Therapeutics Inc. Announces Resignation of Ujwala Mahatme as Member of its Board	CI

Evolution of the average Target Price on Summit Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

07832449622e51dee31eed225285.u7gY5LlMy_VPLPEKmt8omUqS-ULmWW8yc9uNfAdL-e0.z_1Ip4wO_6UBQbNn7fJNqX3HtwCfPgt_HoznCjY7yrLTjH2w2nq_oj99uA~c91aebd13ce839ba3ceca55b4c14be5a

Analyst Recommendations on Summit Therapeutics Inc.

Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating	06-03	MT
Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	05-07	MT
Stifel Initiates Summit Therapeutics With Buy Rating, $8 Price Target	03-26	MT
Summit Therapeutics to Present Research Updates At the 31St Annual ECCMID Conference, Including A Top-Rated ePoster	01/07/21	CI
SUMMIT THERAPEUTICS : HC Wainwright Downgrades Summit Therapeutics to Neutral from Buy	18/11/20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.258 GBP

Average target price

10.58 GBP

Spread / Average Target

+69.09%

High Price Target

10.95 GBP

Spread / Highest target

+74.91%

Low Price Target

10.22 GBP

Spread / Lowest Target

+63.27%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Summit Therapeutics Inc.

Stifel Nicolaus
Citigroup

Quarterly revenue - Rate of surprise

Company calendar